Julie Vose, MD, MBA, Discusses Novel Treatment Options for Hematologic Malignancies

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, about how patients have numerous novel treatment options. She highlighted how these new options can work alone or potentially as part of a combination regimen in future treatment strategies. 

Transcript:

The interesting aspects are looking at not only new drugs, new monoclonal antibodies, new CAR T-cells, [or] new bispecific antibodies. Looking at all these different modalities that can be utilized for all different types of hematologic malignancies, either alone or potentially in the future, combined together [is interesting]. We are going to have so many potential treatments that we will be able to [utilize to] help more patients and be able to get these new novel therapies to many more people.

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content